## **Technical Data Sheet**

# **Biotin Mouse Anti-Human CD178**


#### **Product Information**

Material Number:	556373
Alternate Name:	Fas Ligand; CD95 Ligand
Size:	0.1 mg
Concentration:	0.5 mg/ml
Clone:	NOK-1
Immunogen:	Mouse T lymphoma cells (L5178Y) expressing human FasL
Isotype:	Mouse IgG1
Reactivity:	QC Testing: Human
Storage Buffer:	Aqueous buffered solution containing ≤0.09% sodium azide.

#### Description

Fas (CD95; APO-1) is a 45 kDa cell surface protein that mediates apoptosis when cross-linked with agonistic anti-Fas antibodies or by Fas ligand (FasL; CD178). Fas belongs to the TNF (Tumor Necrosis Factor)/NGF (Nerve Growth Factor) receptor family, and is expressed in various tissues and cells including the thymus, liver, ovary and lung. CD178 (FasL), a member of the TNF cytokine family, induces apoptosis by binding to Fas, its cell-surface receptor. FasL may exist as either membrane bound or soluble forms and is expressed by activated T and NK cells. FasL may also be constitutively expressed in some immunologically privileged sites, e.g., eye and testis. Fas and FasL play an important role in the induction of apoptosis, and thus regulate a variety of immunological responses.

The NOK-1 antibody clone has been reported to recognize human FasL, recognizing both the membrane bound (FasL) and soluble (sFasL) forms. It is reported that the epitope for NOK-1 has been mapped to the COOH-terminus of FasL, at the region implicated in Fas binding. FasL and sFasL have been reported to migrate at reduced molecular weights of 40 and 26 kDa, respectively. However, the molecular weights observed in a particular sample may vary according to FasL and sFasL glycosylation and breakdown patterns as described in the literature. The NOK-1 antibody clone is not recommended for the western blot application.



Flow cytometric analysis of human Fas Ligand (FasL). The mouse T cell lymphoma cell line, L5187Y was transfected with human FasL cDNA and treated with a metalloproteinase inhibitor, K88301 (left panel). K88301 blocks FasL cleavage resulting in high levels of cell surface FasL. As expected, FasL was not detected in the parental L5187Y cells after KB8301 treatment (right panel). The data was generated using a 2-step procedure with either biotin-labeled, isotype-matched control antibody (dashed line) or biotin-labeled (NOK-1, Cat. No. 556373) (solid line) followed by Streptavidin-PE.

#### **Preparation and Storage**

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with biotin under optimum conditions, and unreacted biotin was removed. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

### **BD Biosciences**

bdbiosciences.com						
United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean	
877.232.8995	888.259.0187	32.53.720.550	0120.8555.90	65.6861.0633	55.11.5185.9995	
For country-specific contact information, visit <b>bdbiosciences.com/how_to_order</b> /						
Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation						
of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the						
use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone						
product or as a component of another product. Any use of this product other than the permitted use without the express						
written authorization of Becton Dickinson and Company is strictly prohibited.						
For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.						
BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2008 BD						



#### Application Notes

#### Application

Flow cytometry	Routinely Tested
Western blot	Not Recommended

#### **Recommended Assay Procedure:**

Biotin-conjugated NOK-1 (Cat. No. 556376) is recommended for this application (titrate between 0.06 to 1  $\mu$ g/1x10<sup>6</sup> cells). Biotin-conjugated NOK-1 is also available in a 100 test size (Cat. No. 556374), and has been optimally titrated for use in flow cytometry. NOK-1 has also been used for immunoprecipitation (see purified format, Cat. No. 556372), and to neutralize the cytotoxic activity of FasL. The NA/LE<sup>TM</sup> format of NOK-1 (Cat. No. 556371) should be used for all functional assays. NOK-1 and a related human FasL clone, NOK-2 (purified, Cat. No. 556376; BD NA/LE<sup>TM</sup>, Cat. No. 556375) may give different profiles in neutralization assays. It is thought that NOK-1 and NOK-2 recognize different FasL epitopes. Neither NOK-1 and NOK-2 are suggested for western blot analysis. Clone G247-4 (Cat. No. 556387) is suggested for western blot.

#### **Suggested Companion Products**

Catalog Number	Name	Size	Clone
555747	Biotin Mouse IgG1 κ Isotype Control	100 tests	MOPC-21

#### Product Notices

- 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- 2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
- 3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

#### References

Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997; 18(5):240-244.(Biology)

Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. *J Exp Med.* 1995; 182(6):1777-1783.(Clone-specific: Flow cytometry, Neutralization)

Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. *Immunol Today*. 1995; 16(12):569-574.(Biology) Orlinick JR, Elkon KB, Chao MV. Separate domains of the human fas ligand dictate self-association and receptor binding. *J Biol Chem*. 1997; 272(51):32221-32229.(Clone-specific: Immunoprecipitation, Neutralization)

Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, and Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. *Cell.* 1994; 76(6):969-976. (Biology)

Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. *EMBO J.* 1995; 14(6):1129-1135.(Biology)